When a biotech company faced delays in its global Phase III ovarian cancer study, it reached out to Worldwide. Worldwide was faced with the complex challenge of taking over a global trial involving approximately 400 patients across 136 sites in 12 countries. Worldwide stepped in and ultimately enabled the sponsor to submit their ovarian cancer therapy for regulatory approval on time and without compromise.
Read our case study to learn about how Worldwide’s oncology team used their expertise to:
- Seamlessly transition study operations
- Migrate to a new EDC system, completing patient enrollment on schedule, and coding over 12,000 medical terms
- Maintain data integrity and ensure regulatory readiness.
